Akeso Pharma of Zhongshan formed a $100 million JV with Chia Tai Tianqing Pharma (CTTQ), a subsidiary of Sino Biopharma, to develop and commercialize its clinical-stage anti-PD-1 mAb. CTTQ will contribute $50 million to the JV for a 50% stake. Akeso will add marketing rights to AK105, IP and technology for its half. CTTQ will be in charge of marketing the immunotherapy. According to Akeso, clinical tests of AK105 have shown it has better anti-tumor cell activity than its competitors. AK105 is also approved to start US trials.
Source: China Biotoday
